A new treatment of alopecia induced by palbociclib: Topical cetirizine.
Administration, Topical
Aged
Alopecia
/ chemically induced
Antineoplastic Agents
/ adverse effects
Breast Neoplasms
/ complications
Cetirizine
/ administration & dosage
Cyclin-Dependent Kinases
/ antagonists & inhibitors
Female
Histamine H1 Antagonists
/ administration & dosage
Humans
Neoplasm Metastasis
/ drug therapy
Piperazines
/ adverse effects
Protein Kinase Inhibitors
/ adverse effects
Pyridines
/ adverse effects
Scalp
/ pathology
Treatment Outcome
CDK4/6 inhibitors
Topical cetirizine
alopecia
hair loss
palbociblib
Journal
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
pubmed:
13
6
2020
medline:
30
3
2021
entrez:
13
6
2020
Statut:
ppublish
Résumé
Recently CDK4/6 inhibitors have been introduced for the treatment of hormone positive breast cancer resistant to endocrine therapy. Among their side effects, alopecia is often reported being associated to patients' distress and depressive symptoms. We report the case of a 70-year-old woman affected by breast cancer in treatment with Palbociclib, who developed alopecia.Management and Outcome: We prescribed a topical solution with cetirizine. Global photography, trichoscopy and trichogram were assessed. All evaluations demonstrated alopecia improvement. Currently, no treatment options for CDK 4/6 inhibitors induced alopecia have been proposed. Herein, we report the use of topical cetirizine.
Identifiants
pubmed: 32529951
doi: 10.1177/1078155220930334
doi:
Substances chimiques
Antineoplastic Agents
0
Histamine H1 Antagonists
0
Piperazines
0
Protein Kinase Inhibitors
0
Pyridines
0
Cyclin-Dependent Kinases
EC 2.7.11.22
palbociclib
G9ZF61LE7G
Cetirizine
YO7261ME24
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM